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Abstract
The slow-releasing hydrogen sulfide (H2S) donor, GYY4137, caused concentration-dependent killing of seven different
human cancer cell lines (HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11 and U2OS) but did not affect survival of normal
human lung fibroblasts (IMR90, WI-38) as determined by trypan blue exclusion. Sodium hydrosulfide (NaHS) was less potent
and not active in all cell lines. A structural analogue of GYY4137 (ZYJ1122) lacking sulfur and thence not able to release H2S
was inactive. Similar results were obtained using a clonogenic assay. Incubation of GYY4137 (400 mM) in culture medium led
to the generation of low (,20 mM) concentrations of H2S sustained over 7 days. In contrast, incubation of NaHS (400 mM) in
the same way led to much higher (up to 400 mM) concentrations of H2S which persisted for only 1 hour. Mechanistic studies
revealed that GYY4137 (400 mM) incubated for 5 days with MCF-7 but not IMR90 cells caused the generation of cleaved
PARP and cleaved caspase 9, indicative of a pro-apoptotic effect. GYY4137 (but not ZYJ1122) also caused partial G2/M arrest
of these cells. Mice xenograft studies using HL-60 and MV4-11 cells showed that GYY4137 (100–300 mg/kg/day for 14 days)
significantly reduced tumor growth. We conclude that GYY4137 exhibits anti-cancer activity by releasing H2S over a period
of days. We also propose that a combination of apoptosis and cell cycle arrest contributes to this effect and that H2S donors
should be investigated further as potential anti-cancer agents.
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Introduction
Hydrogen sulfide (H2S) is synthesized naturally from cysteine by
several enzymes including cystathionine c lyase (CSE), cystathio-
nine b synthetase (CBS) and 3-mercaptosulfurtransferase (3-MST)
in a wide range of mammalian and non-mammalian cells both in
vitro and in vivo. In the last decade, numerous physiological and
pathophysiological roles have been proposed for this gas along
with a plethora of cellular and molecular targets including a range
of ion channels, enzymes and transcription factors [1].
Apart from its potential roles in normal physiology there is also
a comprehensive literature describing the toxicity of H2S and its
role as an environmental pollutant [2]. A number of studies have
investigated the role of H2S in triggering cell death and evidence
has been presented that this gas can exert both pro- and anti-
apoptotic activity in cultured cells [3,4]. However, the precise
mechanism(s) involved remain unclear.
Perhaps surprisingly, there have been few studies of the effect of
H2S on cancer cells in vitro and no reports of its effect on tumor
progression in vivo. Several years ago we reported that H2S
protected colon cancer cells (HCT-116) from apoptosis due to b-
phenylethyl isothiocyanate [5]. Others have subsequently reported
that H2S increases human colon cancer cell proliferation and
reduces apoptosis in several cell lines (e.g. HCT-116, [6]) whilst
decreasing survival in other human colon cell lines (e.g. WiDR,
[7]). These disparate observations are difficult to reconcile.
However, one explanation may lie in the choice of H2S donor.
Sulfide salts such as sodium hydrosulfide (NaHS) and sodium
sulfide (Na2S) have been widely used to study the biological effects
of this gas in many cells, tissues and animals. On addition of water,
these salts generate a large amount of H2S over a short time
period. Since cell culture takes place over a period of hours or
days, it is likely that little, if any, H2S is present in medium within a
short time of adding either NaHS or Na2S. Thus, whilst no direct
measurements have been made up to this point, it seems likely that
the concentration of H2S that cancer (or indeed other) non-cancer
cells are exposed to during culture with NaHS will be high at the
start and not sustained throughout the experiment. Thus, it may
be difficult to draw firm conclusions about the ability of H2S to
affect cancer cell survival using sulfide salts as donor agents.
With this in mind, we previously reported that GYY4137
releases H2S slowly both in aqueous media and when administered
to intact animals over a period of hours to days [8,9]. We have
now compared the effect of GYY4137 and NaHS on survival of a
range of cancer and non-cancer cells in culture and correlated
their effect with changes in concentration of H2S in the medium.
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In addition, we have examined the effect of GYY4137 on tumor
growth using a xenograft model in immunodeficient mice.
Materials And Methods
Protocols were conducted with the approval of National
University of Singapore (NUS) Institutional Review Board (IRB,
reference code: 09-120E) and NUS Institutional Animal Care and
Use Committee (IACUC, protocol number: 804/05).
Chemical synthesis of GYY4137 and ZYJ1122
GYY4137 was synthesized chemically in house as described
previously [8]. ZYJ1122 (morpholin-4-ium diphenylphosphinate)
was synthesized as follows. To a solution of diphenylphosphinic
acid (1.0 mmol, 1.0 equiv.) in dichloromethane (DCM; 2 ml) at
room temperature, morpholine (2.0 mmol, 2.0 equiv.) was added
drop-wise. The reaction was stirred at the same temperature for
1 hour and the product subsequently collected by suction
filtration. The pure product was obtained after washing with cold
DCM. White solid was obtained as 56% yield. 1H NMR
(500 MHz, CDCl3, ppm): d =7.77–7.74 (m, 4H), 7.38–7.32 (m,
6H), 3.77–3.75(m, 4H), 2.95–2.93(m, 4H); LRMS (ESI) m/z 217.2
(M2). The purity and structures of the compounds were verified
using Proton Nuclear Magnetic Resonance Spectrometry (1H
NMR) and Mass Spectrometry (Figures S1, S2, S3, S4).
Measurement of H2S
The generation of H2S from either NaHS (Sigma), GYY4137 or
ZYJ1122 (all 400 mM) was determined in aliquots (100 ml)
withdrawn at timed intervals (up to 7 days) from cultured MCF-
7 cells maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma) as described below. The concentration of H2S
(determined as a combination of free H2S, HS
2 and S22) was
measured spectrophotometrically as described previously [10].
Briefly, medium (100 ml) was mixed with 0.85% w/v zinc acetate/
3% NaOH mixture (1:1 ratio, 100 ml). Methylene blue was then
formed by the addition of N,N-dimethyl-p-phenylenediamine-
dihydrochloride dye and FeCl3 (final concentrations, 2.5 mM and
3.3 mM respectively) and absorbance subsequently monitored at
670 nm. The concentration of H2S (defined as above) was
determined using a standard curve of NaHS (0–400 mM;
R2= 0.9987).
Cell culture and cell viability
All the cell lines except HCT-116 were obtained from American
Type Culture Collection (ATCC). Human cervical carcinoma
(HeLa), colorectal carcinoma (HCT-116), hepatocellular carcino-
ma (Hep G2), osteosarcoma (U2OS), breast adenocarcinoma
(MCF-7) and human diploid lung fibroblasts (IMR90 and WI-38)
were cultured in DMEM supplemented with 10% v/v fetal bovine
serum (FBS; HyClone), penicillin/streptomycin (100 U/ml; Sig-
ma) and L-glutamine (2 mM; Caisson) at 37uC in an atmosphere
of 5% CO2. Human acute promyelocytic leukemia cells (HL-60)
were cultured in DMEM containing 20% v/v FBS whilst human
myelomonocytic leukemia (MV4-11) cells were cultured in RPMI
with 10% v/v FBS under the same incubation conditions. Live cell
populations incubated with NaHS, GYY4137 or ZYJ1122 (400 or
800 mM) were collected after 5 days and counted in triplicate after
staining with trypan blue using a haemocytometer. Concentration
response for GYY4137 (100–1000 mM) were generated in MCF-7,
HL-60 and MV4-11 exposed to drugs for 5 days and the ability to
reduce survival assessed as IC50 values. Colony formation using
MCF-7 cells was also assessed by a clonogenic survival assay as
described elsewhere [11]. Briefly, MCF-7 cells (10,000) were
seeded in triplicate in 6-well plates in the presence of GYY4137,
NaHS or ZYJ1122 (200 to 600 mM) for 10 days until colonies were
readily visible. Colonies were then stained with crystal violet (5%
w/v) and the representative pictures were captured using a
ChemiGenius 2 Bio Imaging System (SynGene Ltd).
In vivo efficacy of GYY4137
The animal experimental protocol has been described previ-
ously [12]. Briefly, female, severe combined immunodeficiency
(SCID) mice (17–20 g, 4–6 weeks old) were bred in house and
maintained throughout in specific pathogen-free (SPF) isolators.
Exponentially growing HL-60 and MV4-11 cells (16107) (.95%
viability) were washed twice in phosphate-buffered saline and
subcutaneously injected into the loose skin between the shoulder
blades and the left front leg of recipient mice. Animals were
treated with either GYY4137 (100, 200 and 300 mg/kg/day, i.p.)
or saline (1 ml/kg/day, i.p.) for 14 days commencing 14 days after
injection of cells at which point mice had palpable tumors of
100 mm3 average size All animals were closely monitored. Weight
and tumor size were measured at daily intervals. For tumor size
measurement, length (L) and width (W) of the tumor were
measured with a caliper, and tumor volume (TV) was calculated as
TV = (L6W2)/2.
Cell Cycle Analysis and Western Blotting
MCF-7 cells (40,000) were incubated in 6-well plates in the
presence or absence of GYY4137 (400 mM) for either 5 or 8 days.
Cells treated with ZYJ1122 were used as a control. To analyze the
cell cycle profile, cells were fixed with 70% v/v ethanol on ice for
at least 2 hours and then stained in propidium iodide solution
(20 mg/ml propidium iodide, 100 mg/ml RNase A and 0.1% v/v
Triton X-100) for 15 min at 37uC. Stained cells were then subject
to DNA content analysis by flow cytometry (Dako CyAn ADP)
and the data obtained was processed using Summit software
(Beckman Coulter). Cell lysates of MCF-7 were subjected to SDS-
PAGE and transferred to polyvinylidene difluoride (PVDF)
membranes. The membranes were blocked in Tris buffered saline
(TBS) containing non-fat dry milk (5% w/v) and thereafter
incubated with the relevant primary antibody (1 mg/ml) at 4uC
overnight. Antibodies used were a-PARP, a-cleaved-PARP, a-
cleaved-caspase 9 (Cell Signaling Ltd.) and a-tubulin (Sigma).
Statistical analysis
Cell survival, IC50 and tumor volumes were expressed as mean
6 standard error (SEM). For in vitro studies, cell survival of both
non-treatment (NT) and treatment groups was analyzed using one-
way ANOVA followed by a post-hoc t test. For in vivo studies, the
comparisons between vehicle control group and different dosage
treatments was analyzed using linear mixed model for longitudinal
data analysis by SPSS software (IBM). P,0.05 was considered
significant.
Results
Release of H2S from NaHS and GYY4137 in culture
medium
Incubation of either NaHS or GYY4137 in culture medium
resulted in the release of detectable amounts of H2S as reflected by
an increase in concentration of H2S (mM) following removal of
aliquots and assay for methylene blue formation. Release of H2S
from NaHS was rapid - peaking at or before 20 min and declining
to undetectable levels by 90 min. In stark contrast, H2S release
from GYY4137 was much lower (,10% of that observed with
NaHS) but was sustained, remaining higher than baseline for up to
H2S Donor and Cancer
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7 days. No release of H2S was apparent from ZYJ1122, a control
for GYY4137 lacking sulfur and thus unable to form H2S, under
the same experimental conditions for up to 7 days (Figure 1A).
The chemical structures of GYY4137 and ZYJ1122 are shown in
the inset to Figure 1A.
Effect of NaHS and GYY4137 on cell growth and viability
The effect of NaHS, GYY4137 and ZYJ1122 on growth of
three cancer cell lines i.e. MCF-7 (breast adenocarcinoma), MV4–
11 (acute promyelocytic leukemia) and HL-60 (myelomonocytic
leukemia), was monitored for 5 days. At each indicated interval,
the number of live cells from each treatment group was recorded
in triplicate. GYY4137 (400 mM) significantly reduced cell
proliferation of all three cancer lines whereas both NaHS and
ZYJ1122 were inactive (Figure 1B).
To determine the effect of two different concentrations (400 mM
and 800 mM) of GYY4137, NaHS and ZYJ1122 on a wider panel
of human cancer cell lines, cell survival of a further four cancer cell
lines of different origins i.e. cervical carcinoma (HeLa), colorectal
carcinoma (HCT-116), hepatocellular carcinoma (Hep G2) and
osteosarcoma (U2OS) cells was determined in comparison with
two normal human diploid fibroblasts (WI-38 and IMR90)
(Figure 2A). Over a 5-day culture period, NaHS (400 mM) failed
to influence the survival of any of the seven cancer lines tested. In
contrast, the effect of GYY4137 on cell survival was much more
profound with 30–70% (P,0.01) death in all cancer cell lines at
the same concentration. A higher concentration of NaHS
(800 mM) resulted in a further, albeit small, reduction in HCT-
116, Hep G2 and MCF-7 cell survival (approximately 15–30%)
although again no significant difference in cell survival was
apparent in HeLa, HL-60, U2OS and MV4-11 cells. In contrast,
GYY4137 at the same concentration, markedly reduced survival
by approximately 75–95% in all cancer cell lines. The absolute
degree of cell death caused by GYY4137 varied between cancer
cell lines with greatest effect in HepG2, HL-60, MV4–11, MCF-7
and U2OS cells and least effect in HCT-116 and HeLa cells. For
this reason, subsequent experiments were conducted using one or
more of HL-60, MCF-7 and MV4-11 cancer cells. Importantly,
Figure 1. Differential H2S-releasing manner of NaHS and GYY4137. (A) H2S-releasing profile of NaHS, GYY4137 and ZYJ1122. H2S released
from NaHS, and GYY4137 (400 mM) was determined in aliquots (100 ml) of medium withdrawn at timed intervals (up to 7 days) from cultured MCF-7
cells. Concentration of H2S amounts was assessed spectrophotometrically using N,N-dimethyl-p-phenylenediamine-dihydrochloride and results
showed the H2S concentration (mM). H2S release from GYY4137 was significantly different (P,0.05) from T=0 at all time points from 0.3 hour to 7
days. H2S release from NaHS was significantly different (P,0.05) from T= 0 at all time points up to 1.5 hours. No detectable H2S was released from
ZYJ1122 (400 mM) under identical experimental conditons. Results show mean 6 s.e. mean, n = 3. The chemical structures of GYY4137 and ZYJ1122
are shown in the inset. (B) Growth curve analyses of MCF-7, HL-60 and MV4-11 cells treated with NaHS, GYY4137 and ZYJ1122 (400 mM) over 5 days.
Cell survival was determined by trypan blue staining. Results show cell growth as a percentage relative to NT cell numbers at day 5 and are mean 6
s.e. mean, n = 3.
doi:10.1371/journal.pone.0021077.g001
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neither NaHS nor GYY4137 significantly changed the survival of
human non-cancer WI-38 and IMR90 fibroblasts. The sulfur-
lacking control compound, ZYJ1122, was without significant effect
on the survival of any cell line, suggesting that the observed effects
of GYY4137 on cancer cells are likely due to H2S release. The
concentration response relationship for GYY4137 (100–1000 mM)
to reduce cell survival was also examined in MCF-7, HL-60 and
MV4-11 cells. The IC50 values for this compound were
337.1615.4, 389.3616.8 and 341.8621.2 mM (all n = 3) respec-
tively (Figure 2B).
The effect of NaHS, GYY4137 and ZYJ1122 (200–600 mM) on
survival of MCF-7 cells was also assessed in vitro using a clonogenic
assay. Representative photographs are shown in Figure 2C. For
these experiments, MCF-7 cells were plated in the presence or
absence of drugs and cultured over a 10-day period. GYY4137
caused a concentration dependent loss of cell colony formation
which was close to maximal at a concentration of 600 mM. Cell
loss was not apparent in both NaHS and ZYJ1122 treated
samples.
The effect of GYY4137 (400 mM, 5 or 8 days) on MCF-7 cells
was also examined using cell cycle analysis. The sub-G1
population of MCF-7 cells exposed to GYY4137 was significantly
higher (P,0.05) compared either to non-treated cells or cells
exposed to the same concentration of ZYJ1122 on day 5
(Figure 3A). Thus, the sub-G1 population of cells treated with
GYY4137 represented 7.5% of the total cell population at day 5
and 14.8% at day 8 of treatment compared with approximately
1% of cells which either did not receive treatment or were exposed
to ZYJ1122 (Figure 3A). In addition, there was a significant
accumulation of 4N-DNA cell population in cells treated with
GYY4137 (to 18.6% and 26.6% after 5 and 8 days of incubation
respectively) as compared to either untreated (14.8%) or ZYJ1122-
treated (14%) cells (Figure 3A). In further experiments, the
possibility that GYY4127 triggers cancer cell death by promoting
apoptosis was also studied. A strong signal for cleaved-PARP and
activated caspase 9 was detected in MCF-7 samples treated with
GYY4137 (400 mM, 5 days) with a greatly reduced signal in cells
treated with ZYJ1122 (Figure 3B). Interestingly, no cleavage of
Figure 2. GYY4137 but not NaHS significantly affected cancer cell survivability. (A) The effect of treatment (5 days) of a range of cancer
and non-cancer cells with NaHS, GYY4137 and ZYJ1122 (400 mM or 800 mM) as determined by trypan blue staining. Results show percentage of cell
viability to non-treatment (NT) following incubation in the absence of drug treatment and are mean 6 s.e. mean, n = 3, (#P,0.05; *P,0.01). (B)
Concentration-response curves showing the effect of GYY4137 treatment for 5 days on survival of MCF-7, HL-60 and MV4-11 cells. Results show mean
6 s.e. mean, n = 3. (C) Representative photographs showing clonogenic survival assays of MCF-7 cells following exposure (5 days, 200–600 mM) to
either NaHS (top row), GYY4137 (middle row) and ZYJ1122 (bottom row). NT= non-treatment.
doi:10.1371/journal.pone.0021077.g002
H2S Donor and Cancer
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21077
PARP and no activation of caspase 9 were observed in IMR90
cells incubated with either GYY4137 or ZYJ1122.
Effect of GYY4137 on tumor growth in vivo
Subcutaneous transplantation of either HL-60 or MV4–11 cells
resulted in time-dependent tumor growth in the SCID mouse
(Figure 4A, B). Tumor volume at the end of the experiment was
30246220 mm3 and 11666199 mm3 (n= 4–6) in animals
receiving daily vehicle injection and administered HL-60 and
MV4-11 cells respectively. Administration of GYY4137 on a daily
basis resulted in a significant (P,0.05) dose related inhibition of
tumor growth in both sets of animals. GYY4137 (at the highest
dose used i.e. 300 mg/kg) administered daily for 14 days reduced
tumor volume by 52.569.2% (n= 6) and 55.365.7% (n= 4) in
HL-60 and MV4–11 injected animals. Although not measured
objectively in these experiments, GYY4137 treatment did not
affect animal weight or gross behavior.
Discussion
We report here that, (i) GYY4137 (but not NaHS) causes a
concentration-dependent reduction in cancer cell survival, (ii)
neither GYY4137 nor NaHS, using identical concentrations and
experimental conditions, affected the survival of normal i.e. non-
cancer cells, (iii) GYY4137 promoted cancer cell (MCF-7) but not
normal cell (IMR90) apoptosis as indicated by measurement of
sub-G1 population and by observation of cleaved PARP and
cleaved caspase 9 and triggered cell cycle arrest of MCF-7 cells in
the G2/M phase, (iv) the H2S concentration detected in medium
containing MCF-7 cells exceeded ‘basal’ levels for up to 7 days
after exposure to GYY4137 but for less than 2 h after exposure to
NaHS, (v) ZYJ1122, a control for GYY4137 lacking sulfur and
thus unable to form H2S, was inactive in all cases and, (vi)
GYY4137 administered daily to immunodeficient mice for 14 days
caused a dose-dependent reduction in tumor growth elicited by
prior injection of one of two human leukemia cell lines.
Thus, the present data reveals, for the first time, an anti-cancer
effect of the slow-releasing H2S donor, GYY4137. All cancer cells
tested were susceptible to this compound albeit to different extents.
It is now well established that NaHS releases large amounts of H2S
over a short time period. In the present experiments, we show that
GYY4137, like NaHS, also releases H2S following incubation in
culture medium containing MCF-7 cells thereby confirming our
previous observation of spontaneous H2S generation in aqueous
media [8]. Since ZYJ1122 exhibited no anti-cancer activity in any
of the in vitro models we conclude that the anti-cancer activity of
both GYY4137 and NaHS (at high concentration) is very likely to
be H2S-dependent. Perhaps surprisingly, GYY4137 exhibited
greater cancer cell killing activity than did NaHS in vitro even
though it leads to markedly lower concentrations of H2S in the cell
medium. Thus, optimal killing of cancer cells by H2S under these
experimental conditions would appear to occur at low concentra-
tions of the gas spread over a period of several days as opposed to a
much higher concentration achieved over a shorter time frame
following exposure of cells to NaHS. It should be noted that whilst
relatively high concentrations of GYY4137 (i.e. 400–800 mM) are
required for this effect, the effective concentration of H2S
generated is much less i.e. ,20 mM based on the measurements
in culture medium. However, we cannot rule out the possibility
that GYY4137 may accumulate inside cancer cells and thereby
Figure 3. GYY4137 induced sub-G1 population and apoptosis in MCF-7. (A) Cell cycle analysis of MCF-7 cells after 5 days (NT and ZYJ1122)
and 5 and 8 days (GYY4137) drug treatment. Insets show percentage distribution of cells in each cell cycle phase. Results shown are indicative of 3
individual experiments. NT: non-treatment. (B) Western blot analysis of apoptosis markers (a-cleaved-PARP, a-cleaved-caspase 9) of MCF-7 and IMR90
treated (5 days) with GYY4137 or ZYJ1122 (both 400 mM). The anti-cleaved caspase-9 antibody used detects the large fragment of caspase-9
following cleavage but does not recognize uncleaved procaspase-9. a-tubulin was used as a loading control. Results shown are indicative of 3
individual experiments.
doi:10.1371/journal.pone.0021077.g003
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release larger amounts of H2S intracellularly. With this proviso in
mind, the present data implies that the rate at which cells are
exposed to H2S as well as the concentration of H2S encountered is
critical in determining the ability of this gas to promote cell killing.
Interestingly, neither GYY4137 nor NaHS caused significant
killing of normal i.e. non-cancer cells suggesting that the effect of
both H2S donors is specific for cancer cells. The mechanism of
action of the cancer cell killing effect of GYY4137 has also been
investigated. Treatment of MCF-7 cells with GYY4137 resulted in
cell cycle arrest in the G2/M phase and promotion of apoptosis as
evidence by increased sub-G1 population as well as the presence of
both cleaved PARP and cleaved caspase 9. No significant effect
either on cell cycle or on apoptosis was apparent in ZYJ1122-treated
cells again suggesting that both of these effects were secondary to the
sustained exposure of cells to low levels of H2S. The ability of H2S to
cause cancer cell killing in this way has not previously been
reported. However, H2S has previously been shown to affect both
cell cycle and apoptosis. For example, H2S promotes cell cycle entry
and proliferation of intestinal IEC-18 cell in vitro by activating
MAPK [13]. H2S can also exhibit both pro- (e.g. [14]) and anti- (e.g.
[15]) apoptotic activity depending on the cell type studied and the
experimental conditions, particularly the concentration of H2S
used. A number of potential molecular targets have been implicated
in the effect of H2S on apoptosis including p38 and caspase-3
[15,16], other MAPK such as MEK and JNK [17] as well as
augmented production of heat shock protein (HSP-90) [18]. Whilst
the precise cellular mechanism of action of GYY4137 remains
unclear, it seems not unreasonable that H2S, released slowly over a
period of several days, may affect redox mechanisms within the cell
to bring about the anti-cancer effect. In this light, it might be of
interest to assess the effect of GYY4137 on reactive oxygen species
generation and anti-oxidant enzyme levels in cancer cells.
In conclusion, GYY4137 exhibits anti-cancer cell activity both
in vitro and in vitro. We propose that GYY4137 breaks down slowly
to yield H2S which, by a combination of cell cycle arrest and
promoting apoptosis, inhibits tumor growth. No cell death was
apparent in non-cancer cells. Whether such cells simply break
down H2S at a faster rate or whether cancer cells are uniquely
sensitive to the killing effect of this gas requires further study. The
finding that cancer cells can be killed selectively when exposed to
relatively small amounts of H2S over a relatively long time period
is the key. This observation needs to be borne in mind in any
future work examining the part played by H2S in cancer cell
survival and also in the development of novel H2S-based anti-
tumor agents.
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Figure S1 1H NMR spectrum of GYY 4137.
(TIF)
Figure S2 Mass spectrometry spectrum of GYY 4137.
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Figure S3 1H NMR spectrum of ZYJ1122.
(TIF)
Figure S4 Mass spectrometry spectrum of ZYJ1122.
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